EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1): clinical trials recruiting now
Fewer than 3 recruiting trials found.
2
Recruiting trials
5
Conditions studied
0
US states with sites
1
Countries
Phase breakdown
Phase 1 2
Phase 2 2
Conditions being studied
| Condition | Trials |
|---|---|
| Pancreatic Ductal Adenocarcinoma (PDAC) | 2 |
| Pancreatic cancer | 2 |
| Metastatic Disease | 1 |
| Unresectable Locally Advanced | 1 |
| Unresectable Locally Advanced or Metastatic Disease | 1 |
Recruiting trials involving EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)
- Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
- Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Common questions
How many recruiting trials involve EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)?
2 recruiting trials across 5 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.